vs
Side-by-side financial comparison of BIO-RAD LABORATORIES, INC. (BIO) and INTERPARFUMS INC (IPAR). Click either name above to swap in a different company.
BIO-RAD LABORATORIES, INC. is the larger business by last-quarter revenue ($693.2M vs $386.2M, roughly 1.8× INTERPARFUMS INC). BIO-RAD LABORATORIES, INC. runs the higher net margin — 103.9% vs 7.3%, a 96.6% gap on every dollar of revenue. On growth, INTERPARFUMS INC posted the faster year-over-year revenue change (6.8% vs 3.9%). INTERPARFUMS INC produced more free cash flow last quarter ($145.0M vs $119.1M). Over the past eight quarters, INTERPARFUMS INC's revenue compounded faster (9.2% CAGR vs 6.5%).
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Inter Parfums Inc is a global prestige fragrance firm that develops, manufactures and distributes perfumes, body care and related cosmetics. It partners with top luxury fashion and lifestyle brands to launch licensed fragrance lines, serving consumers across North America, Europe, Asia Pacific and other key markets via department stores, beauty retailers and official e-commerce channels.
BIO vs IPAR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $693.2M | $386.2M |
| Net Profit | $720.0M | $28.1M |
| Gross Margin | 49.8% | 61.5% |
| Operating Margin | -17.2% | 7.1% |
| Net Margin | 103.9% | 7.3% |
| Revenue YoY | 3.9% | 6.8% |
| Net Profit YoY | 200.6% | 16.0% |
| EPS (diluted) | $26.59 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $693.2M | $386.2M | ||
| Q3 25 | $653.0M | $429.6M | ||
| Q2 25 | $651.6M | $333.9M | ||
| Q1 25 | $585.4M | $338.8M | ||
| Q4 24 | $667.5M | $361.5M | ||
| Q3 24 | $649.7M | $424.6M | ||
| Q2 24 | $638.5M | $342.2M | ||
| Q1 24 | $610.8M | $324.0M |
| Q4 25 | $720.0M | $28.1M | ||
| Q3 25 | $-341.9M | $65.8M | ||
| Q2 25 | $317.8M | $32.0M | ||
| Q1 25 | $64.0M | $42.5M | ||
| Q4 24 | $-715.8M | $24.2M | ||
| Q3 24 | $653.2M | $62.3M | ||
| Q2 24 | $-2.2B | $36.8M | ||
| Q1 24 | $383.9M | $41.0M |
| Q4 25 | 49.8% | 61.5% | ||
| Q3 25 | 52.6% | 63.5% | ||
| Q2 25 | 53.0% | 66.2% | ||
| Q1 25 | 52.3% | 63.7% | ||
| Q4 24 | 51.2% | 64.5% | ||
| Q3 24 | 54.8% | 63.9% | ||
| Q2 24 | 55.6% | 64.5% | ||
| Q1 24 | 53.4% | 62.5% |
| Q4 25 | -17.2% | 7.1% | ||
| Q3 25 | 10.0% | 25.3% | ||
| Q2 25 | 11.8% | 17.7% | ||
| Q1 25 | 4.0% | 22.2% | ||
| Q4 24 | 8.7% | 10.0% | ||
| Q3 24 | 9.9% | 25.0% | ||
| Q2 24 | 15.9% | 18.9% | ||
| Q1 24 | 7.3% | 21.0% |
| Q4 25 | 103.9% | 7.3% | ||
| Q3 25 | -52.4% | 15.3% | ||
| Q2 25 | 48.8% | 9.6% | ||
| Q1 25 | 10.9% | 12.5% | ||
| Q4 24 | -107.2% | 6.7% | ||
| Q3 24 | 100.5% | 14.7% | ||
| Q2 24 | -339.2% | 10.8% | ||
| Q1 24 | 62.9% | 12.7% |
| Q4 25 | $26.59 | $0.88 | ||
| Q3 25 | $-12.70 | $2.05 | ||
| Q2 25 | $11.67 | $0.99 | ||
| Q1 25 | $2.29 | $1.32 | ||
| Q4 24 | $-25.89 | $0.78 | ||
| Q3 24 | $23.34 | $1.93 | ||
| Q2 24 | $-76.26 | $1.14 | ||
| Q1 24 | $13.45 | $1.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5B | $137.1M |
| Total DebtLower is stronger | $1.2B | $176.0M |
| Stockholders' EquityBook value | $7.5B | $880.7M |
| Total Assets | $10.6B | $1.6B |
| Debt / EquityLower = less leverage | 0.16× | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $137.1M | ||
| Q3 25 | $1.4B | $77.5M | ||
| Q2 25 | $1.4B | $53.9M | ||
| Q1 25 | $1.7B | $75.3M | ||
| Q4 24 | $1.7B | $109.3M | ||
| Q3 24 | $1.6B | $78.8M | ||
| Q2 24 | $1.6B | $37.7M | ||
| Q1 24 | $1.6B | $76.1M |
| Q4 25 | $1.2B | $176.0M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | $157.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $7.5B | $880.7M | ||
| Q3 25 | $6.7B | $870.9M | ||
| Q2 25 | $7.1B | $839.4M | ||
| Q1 25 | $6.7B | $788.6M | ||
| Q4 24 | $6.6B | $744.9M | ||
| Q3 24 | $7.5B | $778.5M | ||
| Q2 24 | $6.8B | $717.1M | ||
| Q1 24 | $9.1B | $708.1M |
| Q4 25 | $10.6B | $1.6B | ||
| Q3 25 | $9.7B | $1.6B | ||
| Q2 25 | $10.2B | $1.6B | ||
| Q1 25 | $9.5B | $1.4B | ||
| Q4 24 | $9.4B | $1.4B | ||
| Q3 24 | $10.6B | $1.5B | ||
| Q2 24 | $9.7B | $1.4B | ||
| Q1 24 | $12.6B | $1.3B |
| Q4 25 | 0.16× | 0.20× | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $164.9M | $146.5M |
| Free Cash FlowOCF − Capex | $119.1M | $145.0M |
| FCF MarginFCF / Revenue | 17.2% | 37.5% |
| Capex IntensityCapex / Revenue | 6.6% | 0.4% |
| Cash ConversionOCF / Net Profit | 0.23× | 5.21× |
| TTM Free Cash FlowTrailing 4 quarters | $374.6M | $190.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $164.9M | $146.5M | ||
| Q3 25 | $120.9M | $63.9M | ||
| Q2 25 | $116.5M | $11.9M | ||
| Q1 25 | $129.9M | $-7.4M | ||
| Q4 24 | $124.2M | $138.0M | ||
| Q3 24 | $163.6M | $76.1M | ||
| Q2 24 | $97.6M | $25.5M | ||
| Q1 24 | $69.8M | $-52.0M |
| Q4 25 | $119.1M | $145.0M | ||
| Q3 25 | $89.2M | $57.6M | ||
| Q2 25 | $70.8M | $-3.3M | ||
| Q1 25 | $95.5M | $-8.8M | ||
| Q4 24 | $81.2M | $136.1M | ||
| Q3 24 | $123.4M | $75.4M | ||
| Q2 24 | $55.4M | $24.4M | ||
| Q1 24 | $29.6M | $-53.0M |
| Q4 25 | 17.2% | 37.5% | ||
| Q3 25 | 13.7% | 13.4% | ||
| Q2 25 | 10.9% | -1.0% | ||
| Q1 25 | 16.3% | -2.6% | ||
| Q4 24 | 12.2% | 37.7% | ||
| Q3 24 | 19.0% | 17.8% | ||
| Q2 24 | 8.7% | 7.1% | ||
| Q1 24 | 4.8% | -16.4% |
| Q4 25 | 6.6% | 0.4% | ||
| Q3 25 | 4.9% | 1.5% | ||
| Q2 25 | 7.0% | 4.5% | ||
| Q1 25 | 5.9% | 0.4% | ||
| Q4 24 | 6.4% | 0.5% | ||
| Q3 24 | 6.2% | 0.2% | ||
| Q2 24 | 6.6% | 0.3% | ||
| Q1 24 | 6.6% | 0.3% |
| Q4 25 | 0.23× | 5.21× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | 0.37× | 0.37× | ||
| Q1 25 | 2.03× | -0.17× | ||
| Q4 24 | — | 5.69× | ||
| Q3 24 | 0.25× | 1.22× | ||
| Q2 24 | — | 0.69× | ||
| Q1 24 | 0.18× | -1.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
IPAR
| European Based Operations | $232.7M | 60% |
| United States Based Operations | $155.2M | 40% |
